{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:06:31Z","timestamp":1790798791109,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL108867"],"award-info":[{"award-number":["R01HL108867"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002651","name":"Barth Syndrome Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002651","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0605-5","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T09:41:10Z","timestamp":1489052470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome"],"prefix":"10.1186","volume":"12","author":[{"given":"Yan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin K. L.","family":"Phoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne F.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Glukhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabzali","family":"Javadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric M.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Jefferies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold W.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-5670","authenticated-orcid":false,"given":"Zaza","family":"Khuchua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"605_CR1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.171439","author":"D Acehan","year":"2011","unstructured":"Acehan D, Vaz F, Houtkooper RH, James J, Moore V, Tokunaga C, Kulik W, Wansapura J, Toth MJ, Strauss A, et al. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome. J Biol Chem. 2011. doi:\n                    10.1074\/jbc.M110.171439\n                    \n                  .","journal-title":"J Biol Chem"},{"key":"605_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-23","author":"SL Clarke","year":"2013","unstructured":"Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, Martin RP, Tsai-Goodman B, Garratt V, Ashworth M, et al. Barth syndrome. Orphanet J Rare Dis. 2013. doi:\n                    10.1186\/1750-1172-8-23\n                    \n                  .","journal-title":"Orphanet J Rare Dis"},{"key":"605_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128561","author":"Y Huang","year":"2015","unstructured":"Huang Y, Powers C, Madala SK, Greis KD, Haffey WD, Towbin JA, Purevjav E, Javadov S, Strauss AW, Khuchua Z. Cardiac metabolic pathways affected in the mouse model of barth syndrome. PLoS ONE. 2015. doi:\n                    10.1371\/journal.pone.0128561\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"605_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2013.00074","author":"C Powers","year":"2013","unstructured":"Powers C, Huang Y, Strauss A, Khuchua Z. Diminished exercise capacity and mitochondrial bc1 complex deficiency in tafazzin-knockdown mice. Front Physiol. 2013. doi:\n                    10.3389\/fphys.2013.00074\n                    \n                  .","journal-title":"Front Physiol"},{"key":"605_CR5","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6635","author":"S Jang","year":"2016","unstructured":"Jang S, Lewis TS, Powers C, Khuchua Z, Baines CP, Wipf P, Javadov S. Elucidating mitochondrial electron transport chain supercomplexes in the heart during ischemia-reperfusion. Antioxid Redox Signal. 2016. doi:\n                    10.1089\/ars.2016.6635\n                    \n                  .","journal-title":"Antioxid Redox Signal"},{"key":"605_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31372","author":"JL Jefferies","year":"2013","unstructured":"Jefferies JL. Barth syndrome. Am J Med Genet C: Semin Med Genet. 2013. doi:\n                    10.1002\/ajmg.c.31372\n                    \n                  .","journal-title":"Am J Med Genet C: Semin Med Genet"},{"key":"605_CR7","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2010.199","author":"MS Soustek","year":"2010","unstructured":"Soustek MS, Falk D, Mah C, Toth M, Schlame M, Lewin A, Byrne B. Characterization of a transgenic shRNA induced murine model of tafazzin deficiency. Hum Gene Ther. 2010. doi:\n                    10.1089\/hum.2010.199\n                    \n                  .","journal-title":"Hum Gene Ther"},{"key":"605_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.111.000455","author":"CK Phoon","year":"2012","unstructured":"Phoon CK, Acehan D, Schlame M, Stokes DL, Edelman-Novemsky I, Yu D, Xu Y, Viswanathan N, Ren M. Tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction. J Am Heart Assoc. 2012. doi:\n                    10.1161\/JAHA.111.000455\n                    \n                  .","journal-title":"J Am Heart Assoc"},{"key":"605_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-012-0258-z","author":"SP Hanke","year":"2012","unstructured":"Hanke SP, Gardner AB, Lombardi JP, Manning PB, Nelson DP, Towbin JA, Jefferies JL, Lorts A. Left ventricular noncompaction cardiomyopathy in Barth syndrome: an example of an undulating cardiac phenotype necessitating mechanical circulatory support as a bridge to transplantation. Pediatr Cardiol. 2012. doi:\n                    10.1007\/s00246-012-0258-z\n                    \n                  .","journal-title":"Pediatr Cardiol"},{"key":"605_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.204","author":"WR Thompson","year":"2016","unstructured":"Thompson WR, DeCroes B, McClellan R, Rubens J, Vaz FM, Kristaponis K, Avramopoulos D, Vernon HJ. New targets for monitoring and therapy in Barth syndrome. Genet Med. 2016. doi:\n                    10.1038\/gim.2015.204\n                    \n                  .","journal-title":"Genet Med"},{"key":"605_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pd.2599","author":"CG Steward","year":"2010","unstructured":"Steward CG, Newbury-Ecob RA, Hastings R, Smithson SF, Tsai-Goodman B, Quarrell OW, Kulik W, Wanders R, Pennock M, Williams M, et al. Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth. Prenat Diagn. 2010. doi:\n                    10.1002\/pd.2599\n                    \n                  .","journal-title":"Prenat Diagn"},{"key":"605_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra063052","author":"S Neubauer","year":"2007","unstructured":"Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007. doi:\n                    10.1056\/NEJMra063052\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"605_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.306585","author":"VH Lam","year":"2015","unstructured":"Lam VH, Zhang L, Huqi A, Fukushima A, Tanner BA, Onay-Besikci A, Keung W, Kantor PF, Jaswal JS, Rebeyka IM, et al. Activating PPARalpha prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts. Circ Res. 2015. doi:\n                    10.1161\/CIRCRESAHA.117.306585\n                    \n                  .","journal-title":"Circ Res"},{"key":"605_CR14","doi-asserted-by":"publisher","unstructured":"Brigadeau F, Gele P, Wibaux M, Marquie C, Martin-Nizard F, Torpier G, Fruchart JC, Staels B, Duriez P, Lacroix D. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol. 2007. doi:\n                    10.1097\/FJC.0b013e3180544540\n                    \n                  .","DOI":"10.1097\/FJC.0b013e3180544540"},{"key":"605_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.10.1154","author":"A Tenenbaum","year":"2005","unstructured":"Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005. doi:\n                    10.1001\/archinte.165.10.1154\n                    \n                  .","journal-title":"Arch Intern Med"},{"key":"605_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.55","author":"JP Bonnefont","year":"2010","unstructured":"Bonnefont JP, Bastin J, Laforet P, Aubey F, Mogenet A, Romano S, Ricquier D, Gobin-Limballe S, Vassault A, Behin A, et al. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther. 2010. doi:\n                    10.1038\/clpt.2010.55\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"key":"605_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000118","author":"MC Orngreen","year":"2014","unstructured":"Orngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforet P. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology. 2014. doi:\n                    10.1212\/WNL.0000000000000118\n                    \n                  .","journal-title":"Neurology"},{"key":"605_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-014-9779-3","author":"MC Orngreen","year":"2014","unstructured":"Orngreen MC, Vissing J, Laforet P. No effect of bezafibrate in patients with CPTII and VLCAD deficiencies. J Inherit Metab Dis. 2014. doi:\n                    10.1007\/s10545-014-9779-3\n                    \n                  .","journal-title":"J Inherit Metab Dis"},{"key":"605_CR19","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M034728","author":"MA Kiebish","year":"2013","unstructured":"Kiebish MA, Yang K, Liu X, Mancuso DJ, Guan S, Zhao Z, Sims HF, Cerqua R, Cade WT, Han X, et al. Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome. J Lipid Res. 2013. doi:\n                    10.1194\/jlr.M034728\n                    \n                  .","journal-title":"J Lipid Res"},{"key":"605_CR20","doi-asserted-by":"publisher","DOI":"10.1086\/302261","author":"BS Andresen","year":"1999","unstructured":"Andresen BS, Olpin S, Poorthuis BJ, Scholte HR, Vianey-Saban C, Wanders R, Ijlst L, Morris A, Pourfarzam M, Bartlett K, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet. 1999. doi:\n                    10.1086\/302261\n                    \n                  .","journal-title":"Am J Hum Genet"},{"key":"605_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.07.002","author":"G Karamanlidis","year":"2013","unstructured":"Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz Jr SC, Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, Tian R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013. doi:\n                    10.1016\/j.cmet.2013.07.002\n                    \n                  .","journal-title":"Cell Metab"},{"key":"605_CR22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.99","author":"ME den Boer","year":"2002","unstructured":"den Boer ME, Wanders RJ, Morris AA, IJlst L, Heymans HS, Wijburg FA. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics. 2002. doi:\n                    10.1542\/peds.109.1.99\n                    \n                  .","journal-title":"Pediatrics"},{"key":"605_CR23","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00811.2005","author":"VJ Exil","year":"2006","unstructured":"Exil VJ, Gardner CD, Rottman JN, Sims H, Bartelds B, Khuchua Z, Sindhal R, Ni G, Strauss AW. Abnormal mitochondrial bioenergetics and heart rate dysfunction in mice lacking very-long-chain acyl-CoA dehydrogenase. Am J Physiol Heart Circ Physiol. 2006. doi:\n                    10.1152\/ajpheart.00811.2005\n                    \n                  .","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"605_CR24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00931.2012","author":"D Xiong","year":"2014","unstructured":"Xiong D, He H, James J, Tokunaga C, Powers C, Huang Y, Osinska H, Towbin JA, Purevjav E, Balschi JA, et al. Cardiac-specific VLCAD deficiency induces dilated cardiomyopathy and cold intolerance. Am J Physiol Heart Circ Physiol. 2014. doi:\n                    10.1152\/ajpheart.00931.2012\n                    \n                  .","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"605_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2008.07.006","author":"Y Cheng","year":"2008","unstructured":"Cheng Y, Hauton D. Cold acclimation induces physiological cardiac hypertrophy and increases assimilation of triacylglycerol metabolism through lipoprotein lipase. Biochim Biophys Acta. 2008. doi:\n                    10.1016\/j.bbalip.2008.07.006\n                    \n                  .","journal-title":"Biochim Biophys Acta"},{"key":"605_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvt212","author":"AJ Bakermans","year":"2013","unstructured":"Bakermans AJ, Dodd MS, Nicolay K, Prompers JJ, Tyler DJ, Houten SM. Myocardial energy shortage and unmet anaplerotic needs in the fasted long-chain acyl-CoA dehydrogenase knockout mouse. Cardiovasc Res. 2013. doi:\n                    10.1093\/cvr\/cvt212\n                    \n                  .","journal-title":"Cardiovasc Res"},{"key":"605_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.113.000732","author":"CD Rau","year":"2015","unstructured":"Rau CD, Wang J, Avetisyan R, Romay MC, Martin L, Ren S, Wang Y, Lusis AJ. Mapping genetic contributions to cardiac pathology induced by Beta-adrenergic stimulation in mice. Circ Cardiovasc Genet. 2015. doi:\n                    10.1161\/CIRCGENETICS.113.000732\n                    \n                  .","journal-title":"Circ Cardiovasc Genet"},{"key":"605_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm122","author":"J Seibler","year":"2007","unstructured":"Seibler J, Kleinridders A, Kuter-Luks B, Niehaves S, Bruning JC, Schwenk F. Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res. 2007. doi:\n                    10.1093\/nar\/gkm122\n                    \n                  .","journal-title":"Nucleic Acids Res"},{"key":"605_CR29","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.052928","author":"T Nakajima","year":"2009","unstructured":"Nakajima T, Tanaka N, Kanbe H, Hara A, Kamijo Y, Zhang X, Gonzalez FJ, Aoyama T. Bezafibrate at clinically relevant doses decreases serum\/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. Mol Pharmacol. 2009. doi:\n                    10.1124\/mol.108.052928\n                    \n                  .","journal-title":"Mol Pharmacol"},{"key":"605_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr541","author":"A Johri","year":"2012","unstructured":"Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E, Chandra A, Beal MF. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet. 2012. doi:\n                    10.1093\/hmg\/ddr541\n                    \n                  .","journal-title":"Hum Mol Genet"},{"key":"605_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2012.12.003","author":"N Noe","year":"2013","unstructured":"Noe N, Dillon L, Lellek V, Diaz F, Hida A, Moraes CT, Wenz T. Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy. Mitochondrion. 2013. doi:\n                    10.1016\/j.mito.2012.12.003\n                    \n                  .","journal-title":"Mitochondrion"},{"key":"605_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds355","author":"M Dumont","year":"2012","unstructured":"Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Calingasan NY, Yang L, Tampellini D, Starkov AA, et al. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet. 2012. doi:\n                    10.1093\/hmg\/dds355\n                    \n                  .","journal-title":"Hum Mol Genet"},{"key":"605_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31804b4163","author":"BM Jucker","year":"2007","unstructured":"Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C, Hu TC, Lenhard SC, Costell M, Bernard R, et al. PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J Cardiovasc Pharmacol. 2007. doi:\n                    10.1097\/FJC.0b013e31804b4163\n                    \n                  .","journal-title":"J Cardiovasc Pharmacol"},{"key":"605_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.04.011","author":"C Viscomi","year":"2011","unstructured":"Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggio M, Fagiolari G, Schon EA, Lamperti C, Zeviani M. In vivo correction of COX deficiency by activation of the AMPK\/PGC-1alpha axis. Cell Metab. 2011. doi:\n                    10.1016\/j.cmet.2011.04.011\n                    \n                  .","journal-title":"Cell Metab"},{"key":"605_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr482","author":"S Yatsuga","year":"2012","unstructured":"Yatsuga S, Suomalainen A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet. 2012. doi:\n                    10.1093\/hmg\/ddr482\n                    \n                  .","journal-title":"Hum Mol Genet"},{"key":"605_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044335","author":"LM Dillon","year":"2012","unstructured":"Dillon LM, Hida A, Garcia S, Prolla TA, Moraes CT. Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse. PLoS ONE. 2012. doi:\n                    10.1371\/journal.pone.0044335\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"605_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02158.x","author":"LI Kajosaari","year":"2004","unstructured":"Kajosaari LI, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol. 2004. doi:\n                    10.1111\/j.1365-2125.2004.02158.x\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"key":"605_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.07.006","author":"T Wenz","year":"2008","unstructured":"Wenz T, Diaz F, Spiegelman BM, Moraes CT. RETRACTED: activation of the PPAR\/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab. 2008. doi:\n                    10.1016\/j.cmet.2008.07.006\n                    \n                  .","journal-title":"Cell Metab"},{"key":"605_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.02.019","author":"PS Prince","year":"2010","unstructured":"Prince PS, Sathya B. Pretreatment with quercetin ameliorates lipids, lipoproteins and marker enzymes of lipid metabolism in isoproterenol treated cardiotoxic male Wistar rats. Eur J Pharmacol. 2010. doi:\n                    10.1016\/j.ejphar.2010.02.019\n                    \n                  .","journal-title":"Eur J Pharmacol"},{"key":"605_CR40","doi-asserted-by":"crossref","unstructured":"Olsson AG, Lang PD. Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia. Atherosclerosis. 1978;(4):421\u20138.","DOI":"10.1016\/0021-9150(78)90137-5"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-017-0605-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T06:27:31Z","timestamp":1589524051000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0605-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0605-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727389368.793548267","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]},"assertion":[{"value":"1 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"49"}}